TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02794090

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care, individual visits
Description: Randomized controlled study of two types of delivering behavioral treatment to Children suffering from obesity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone coaching
Description: Randomized controlled study of two types of delivering behavioral treatment to Children suffering from obesity.
Study: NCT02360553

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ObeseGO!
Description: The intervention group were received the obeseGO! intervention which is an internet-based intervention. The participants and the parents who are randomly chosen to enroll in this intervention group were provided with the ObeseGO! website. The website was accessed at www.obesego.com. The website consists of various informations on healthy lifestyle, diet and ways to overcome obesity.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Pamphlets material
Description: The control group will be given pamphlets material on diet and physical activity.
Study: NCT03831737

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: stretching exercises
Description: Head/neck stretches~* Head tilt side to side~* Cross-chest stretch Torso stretches~* Side stretch~* Mid-back stretch Lower limb~* Standing quadriceps stretch~* Standing hamstring stretch

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: stretching exercises
Description: Head/neck stretches~* Head tilt side to side~* Cross-chest stretch Torso stretches~* Side stretch~* Mid-back stretch Lower limb~* Standing quadriceps stretch~* Standing hamstring stretch
Study: NCT00682240

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laser treatment with PASCAL®
Description: panretinal laser treatment - single-session

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laser treatment with PASCAL®
Description: panretinal laser treatment - multi-session

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laser treatment with PASCAL®
Description: grid / focal laser treatment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laser treatment with conventional laser system
Description: panretinal laser treatment - multi-session according to the conventional protocol, using a conventional laser system
Study: NCT03077035

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: glass ionomer sealants

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: resin-based sealant
Study: NCT00875303

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Play Nicely program
Description: The intervention was the Play Nicely program, a multimedia educational program. Permission to demonstrate the program to multiple viewers was obtained from the copyright holder. English speaking caregivers viewed the 2nd English language edition and Spanish speaking caregivers viewed the Spanish edition. In the program, there are 16 options (20 options in the Spanish version) to respond to the hypothetical situation of witnessing a young child have hurtful behavior toward another child. Caregivers in the intervention group were instructed to view 4 of the interactive options of their choosing. On average, it takes 1 minute to view one option. Parents in the control group received routine primary care with their pediatrician.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Routine primary care.
Study: NCT03244943

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Non surgical periodontal Treatment
Description: The NSPT, which consisted of subgingival debridement - scaling and root planning (SRP) under local anesthesia. On average, the treatment of the entire oral cavity was completed within four sessions (sessions of 50 minutes). The SRP was performed by one experienced periodontist (KRVV) using Gracey curettes (Hu-Friedy MFG. Co. Inc., Chicago, IL, USA), ultra-sonic devices (Bob-Cat, Dentsply/Cavitron, Long Island City, NY, USA) and, if necessary, with multilaminated drills.
Study: NCT05348980

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine Hydrochloride 4 mg
Description: Intramuscular Phenylephrine HCL 04 mg were administered as prophylactic stat dose in Vastus lateralis muscle of thigh 05 minutes before giving spinal anesthesia.
Study: NCT02604615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine(Aibin)
Description: capecitabine(Aibin):625mg/m2,bid d1-5; q1w, po,5 or 10 weeks in total

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine(Aibin)
Description: capecitabine(Aibin):625mg/m2,bid d1-5; q1w, po,5 or 10 weeks in total

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin(Aiheng)
Description: Oxaliplatin(Aiheng):65mg/m2,d1,8,22,29,I.V. or Oxaliplatin(Aiheng):65mg/m2,d1,8,22,29,43,50,64,71,I.V.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin(Aiheng)
Description: Oxaliplatin(Aiheng):65mg/m2,d1,8,22,29,I.V. or Oxaliplatin(Aiheng):65mg/m2,d1,8,22,29,43,50,64,71,I.V.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: concurrent radiotherapy:50Gy in total,2 Gy/d,5d/w,Until disease progression or unacceptable toxicity

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: concurrent radiotherapy:50Gy in total,2 Gy/d,5d/w,Until disease progression or unacceptable toxicity
Study: NCT01771367

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluad

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Agrippal

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01039636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FBS0701
Description: Oral FBS0701 for 7 days at one of the following doses: 3 mg/kg/day or 8 mg/kg/day or 16 mg/kg/day or 32 mg/kg/day or 40 mg/kg/day
Study: NCT05348980

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine Hydrochloride 8 mg
Description: Intramuscular Phenylephrine HCL 08 mg were administered as prophylactic stat dose in Vastus lateralis muscle of thigh 05 minutes before giving spinal anesthesia.
Study: NCT01764230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triptorelin
Description: Throughout the course of chemotherapy, patients were administered triptorelin (Diphereline SR 3 mg, Ibsen) in the form of i.m. injections, always once a month and simultaneously with the chemotherapy.
Study: NCT04145713

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic mixture
Description: The experimental intervention will consist in administrating a high-dose multi-strain probiotic (SIVOMIXXTM) for 30 days in addition to hypothermic therapy. The administration of probiotics will begin during the first 24 hours of hypothermia, at the dose of 1 capsule open in 5 millilitre of water. It will be administered daily for 30 days, either via nasogastric tube or orally.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The comparison intervention will consist in administrating placebo for 30 days in addition to hypothermic therapy. The administration of placebo will begin during the first 24 hours of hypothermia, at the dose of 1 capsule open in 5 millilitre of water. It will be administered daily for 30 days, either via nasogastric tube or orally.
Study: NCT05159362

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Software Application
Description: Access is granted to participants for 4 weeks to the OARSCM platform which includes reinforcements for meeting MOUD treatment goals.
Study: NCT00395213

Intervention type: DRUG
Intervention: Selective serotonin reuptake inhibitor (SSRI) and serotonin-norepinephrine reuptake inhibitor (SNRI) medications
Description: Treatment with SSRIs or SNRIs
Study: NCT01335698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir Sulphate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Study: NCT01484262

Intervention type: DRUG
Intervention: liraglutide
Description: Patients will be treated according to routine clinical practice at the discretion of the treating physician according to current labelling.

Intervention type: DRUG
Intervention: insulin
Description: Any insulin in any device available on the market may be used by patients as part of routine clinical practice according to current labelling.
Study: NCT01959035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole once-monthly
Description: 400 or 300 mg/month; 6 intramuscular (IM) injections starting at baseline
Study: NCT03073785

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Given IV
Study: NCT01879254

Intervention type: DEVICE
Intervention: Deep Brain Stimulation
Study: NCT03073785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03744195

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group I Experimental Kinesotaping
Description: For application of kinesotaping following procedure will be adopted:~1. The skin will be cleaned properly with alcohol~2. The first strip will be applied in Y-shape (15-20% stretch) surrounding the deltoid muscle to provide inhibition and muscle relaxation~3. A second strip (I-shape) will be applied for functional correction (50-75% stretch), passing over the supraspinatus, trapezius, glenohumeral joint and middle deltoid Daily Strengthening Exercises (3 sets / 10\~30 reps) Joint mobilization (3 sets / 60 seconds hold / 30 seconds interval) Stretching Exercises (3 sets / 30 seconds hold / 30 seconds interval

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group II conventional training group
Description: Joint mobilization (3 sets / 60 seconds hold / 30 seconds interval) Stretching Exercises (3 sets / 30 seconds hold / 30 seconds interval) Strengthening Exercises (3 sets / 10\~30 reps)
Study: NCT03127696

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: FMT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: FMT

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Modification Program
Description: Lifestyle

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Lifestyle Modification Program
Description: Lifestyle

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham
Study: NCT03298698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab: 375 mg/m2 intravenously on day 0 and day 14 B-cells will be monitored weekly, and if no complete depletion is achieved, additional dose(s) of Rituximab will be given at a weekly interval until complete B cell depletion (maximum of 2 additional doses).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone 1 mg/kg/day (max 80 mg/day) for 8 weeks
Study: NCT05005091

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral carbohydrate
Description: 100 ml oral carbohydrate two hours ago preoperatively
Study: NCT03923075

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: INFUSION BEFORE INDUCTION OF ANAESTHESIA

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline
Description: INFUSION BEFORE INDUCTION OF ANAESTHESIA
Study: NCT04308018

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: S2alar-iliac screws
Description: Caudal end of the instrumentation at iliac bone via S2alar-iliac screws
Study: NCT03162341

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasonography
Description: The tophus volume will be assess using ultrasonography.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DECT
Description: The tophus volume will be assess using dual-energy computed tomography (DECT).
Study: NCT04308018

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: S1 screws
Description: Caudal end of the instrumentation at S1
Study: NCT04014894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ET019003-T Cells
Description: Fludarabine 25 mg/day on day -5, -4 and -3; Cyclophosphamide 250 or 300 mg/day on day -5, -4 and -3; ET019003-T Cells on day 0.
Study: NCT01537471

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meclizine
Description: Meclizine 12.5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meclizine
Description: Meclizine 25 mg
Study: NCT03073785

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo hypofractionated stereotactic radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo hypofractionated stereotactic radiotherapy
Study: NCT03353662

Intervention type: OTHER
Intervention: Women of Gamo Gofa
Description: The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the women of Gamo Gofa between 15-49 years by measuring hemoglobin (Hb), plasma ferritin (PF), soluble transferrin receptor (sTfR), C-reactive protocol (CRP), alpha-1-acid glycoprotein (AGP), plasma Zn (PZn), plasma retinol and retinol binding protein (RBP), respectively.

Intervention type: OTHER
Intervention: Children of Gamo Gofa
Description: The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the children of Gamo Gofa between 6-59 months by measuring hemoglobin (Hb), plasma ferritin (PF), soluble transferrin receptor (sTfR), C-reactive protocol (CRP), alpha-1-acid glycoprotein (AGP), plasma Zn (PZn), plasma retinol and retinol binding protein (RBP), respectively.

Intervention type: OTHER
Intervention: Women of West Gojjam
Description: The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the women of West Gojjam between 15-49 years by measuring hemoglobin (Hb), plasma ferritin (PF), soluble transferrin receptor (sTfR), C-reactive protocol (CRP), alpha-1-acid glycoprotein (AGP), plasma Zn (PZn), plasma retinol and retinol binding protein (RBP), respectively.

Intervention type: OTHER
Intervention: Children of West Gojjam
Description: The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the children of West Gojjam between the age of 6-59 months by measuring hemoglobin (Hb), plasma ferritin (PF), soluble transferrin receptor (sTfR), C-reactive protocol (CRP), alpha-1-acid glycoprotein (AGP), plasma Zn (PZn), plasma retinol and retinol binding protein (RBP), respectively.

Intervention type: OTHER
Intervention: Women of Kamashi
Description: The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the women of Kamashi between 15-49 years by measuring hemoglobin (Hb), plasma ferritin (PF), soluble transferrin receptor (sTfR), C-reactive protocol (CRP), alpha-1-acid glycoprotein (AGP), plasma Zn (PZn), plasma retinol and retinol binding protein (RBP), respectively.

Intervention type: OTHER
Intervention: Children of Kamashi
Description: The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the children of Kamashi between 6-59 months by measuring hemoglobin (Hb), plasma ferritin (PF), soluble transferrin receptor (sTfR), C-reactive protocol (CRP), alpha-1-acid glycoprotein (AGP), plasma Zn (PZn), plasma retinol and retinol binding protein (RBP), respectively.
Study: NCT00400855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Description: Study drug
Study: NCT02503085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nurofen for Children®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nurofen for Children®

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Algifor Dolo Junior®

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Algifor Dolo Junior®
Study: NCT04832529

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No packing of perianal abscess cavity
Description: introducing new method to no packing of abscess cavity.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No packing of perianal abscess cavity
Description: introducing new method to no packing of abscess cavity.
Study: NCT05134168

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bone marrow mononuclear cell injection
Description: bone marrow mononuclear cells were injected in the intersphincteric space and around the internal opening after ligation and division of the tract

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LIFT
Description: The fistula tract is ligated in the intersphincteric space

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LIFT
Description: The fistula tract is ligated in the intersphincteric space
Study: NCT03407170

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: 200 mg by IV infusion Q3W for up to 24 months
Study: NCT00050960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bexarotene with carboplatin and paclitaxel
Description: bexarotene capsules (400 mg/m\^2/day) in combination with carboplatin IV (AUC 6) every 3 weeks and paclitaxel IV (200 mg/m\^2) every 3 weeks. Subjects in this group also received an antilipid agent which was selected at the discretion of the investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin and paclitaxel
Description: carboplatin IV (AUC 6) every 3 weeks and paclitaxel IV (200 mg/m\^2) every 3 weeks.
Study: NCT02727660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BFF MDI (PT009) 320/9.6 μg
Description: Blinded Treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BFF MDI (PT009) 160/9.6 μg
Description: Blinded Treatment
Study: NCT00393029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 60 mg/kg/day x 2 days intravenously in 250ml dextrose 5% in water (D5W) with mesna 15 mg/kg/day x 2 days over 1 hour.
Study: NCT00843440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5 mg / kg every 14 days with a total of 6 injections.A two-phase Gehan method will be used with a first phase designed to eliminate a non effective treatment quickly and a second phase allowing assessment of efficacy.
Study: NCT03040089

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PICO+4
Description: picosecond, neodymium-doped yttrium aluminum garnet laser

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Neoquine Cream 2%
Description: 2% hydroquinone cream

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoquine Cream 2%
Description: 2% hydroquinone cream
Study: NCT03456219

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal protein diet
Description: The intervention with the control diet was composed of 65% of carbohydrates, 15% of proteins and 20% of lipids.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-protein diet
Description: The intervention with the higher-protein diet was composed of 45% of carbohydrates, 35% of proteins and 20% of lipids.
Study: NCT02727660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF MDI (PT005) 9.6 μg
Description: Blinded Treatment
Study: NCT04273009

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Renew VS PTNS
Description: These will be prescribed and applied as described above.
Study: NCT02455102

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electronic warning alert
Description: A newly-installed warning system for stroke prevention in atrial fibrillation.
Study: NCT03073785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid
Description: Given IV
Study: NCT03847103

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robotic-assisted Therapy with Bilateral Practice
Description: 40-minute robotic-assisted therapy with bilateral practice program for wrist and forearm repetitive movement training was performed during each session.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Unilateral Task-specific Training
Description: 40 -minute unilateral task-specific training using various tasks: picks up beans with spoon, pouring water from one glass to another glass, opening and closing a drawer, drinking from a mug, and wiping the table were chosen for facilitating multitude of upper extremity functions. Three tasks per session were chosen for various specific components of hand-arm function training.
Study: NCT01558596

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Preconditioning
Description: Blood pressure cuff inflated to 200 mmHg in the upper extremity for 5 minutes to cause forearm ischemia by external compression of the brachial artery. This will be followed by 5 minutes of cuff deflation to allow for preperfusion. The ischemia-reperfusion cycle will be repeated 3 times for a total duration of 30 minutes, equally divided between ischemia and reperfusion.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Blood pressure cuff inflated to 40-50 mmHg in the upper extremity
Study: NCT03890523

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Airway stent implantation
Description: The segmented airway stent modified with 3D printing were implanted to treat gastro-respiratory fistula involving carina and distal bronchi. The stents were removed because of stent-related complications or tracheobronchial healing.
Study: NCT03547908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF
Description: 50/200/25 mg B/F/TAF FDC tablet administered orally once daily, without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF
Description: 50/200/25 mg B/F/TAF FDC tablet administered orally once daily, without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match DTG
Description: Tablet administered orally once daily, without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match F/TDF
Description: Tablet administered orally once daily, without regard to food

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DTG
Description: 50 mg tablet administered orally once daily, without regard to food

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: F/TDF
Description: 200/300 mg tablet administered orally once daily, without regard to food

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to match B/F/TAF
Description: Tablet administered orally once daily, without regard to food